The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China

Table 1 General information of patients enrolled

Clinical details	Stage II empyema n = 65	Stage III empyema n = 374	P
Sex (n,%)
Male	45 (69.23)	301(80.48)	0.06
Femaile	20(30.77)	73 (19.52)
Age(years, median )	29 (20, 45)	41 (25, 68)	0.01*
Diabetes (n,%)	2(3.08)	30 ( 8.02)	0.25
Duration of clinical symptoms
>6 months (n,%)	5(7.69)	82 (21.92)	0.01*
Location of disease
Left	28(43.08)	166 (44.39)	0.84
Right	37(56.92)	200 (53.48)
Both sides	0(0.00)	8(2.13)
History of *ATT
Newly-diagnosed	50(76.92)	45(12.03)	0.00**
Retreated	15(23.08)	329 (87.97)
Duration of ATT* before surgery (weeks, Median)	6 (4 ,12)	19 (12, 30)	0.01**
Bronchopleural fistula	0 (0.00)	45 ( 12.03%)	0.00**
Drug-resistant TB (n,%)	2 (3.08)	9 (2.41)	0.91
Lung function(Percentage of predicted values, %)
FEV1*	60.7% ± 10.7%	49.1% ± 18.4%	0.02**
FVC*	70.5% ± 13.6%	62.5% ± 15.1%

ISSN: 1471-2466